|
|
Methylol Cephalexin Lysinate
(¸ÞÄ¥¿Ã¼¼ÆÈ·º½Å¸®Áö³×ÀÌÆ®)
|
|
|
|
Therapeutic Classification |
- Cephalosporins; First Generation
|
|
Mechanism of Action |
- Cephalexin¿¡ -methylol±â°¡ ºÙÀº ±¸Á¶·Î¼ cephalexinº¸´Ù ÀÛ¿ëÁö¼Ó½Ã°£ÀÌ ±æ´Ù°í Á¦Á¶È¸»ç¿¡¼´Â º¸°íÇÏ¿´´Ù.
- Cephalexin :
- 1¼¼´ë cephalosporin°è Ç×»ýÁ¦·Î¼, ±×¶÷¾ç¼º±Õ ¹× ÀϺΠȣ±â¼º ±×¶÷À½¼º °£±Õ (¿¹, E. coli, Klebsiella, Proteus mirabilis)¿¡ »ì±Õ È¿°ú¸¦ ³ªÅ¸³½´Ù.
- ¿©·¯ °¡Áö penicillin-°áÇÕ ´Ü¹é(PBPs)¿¡ °áÇÕÇÏ¿© ¼¼±Õ ¼¼Æ÷º®ÀÇ peptidoglycan ÇÕ¼ºÀÇ ¸¶Áö¸· transpeptidation ´Ü°è¸¦ ¾ïÁ¦ÇÔÀ¸·Î½á ¼¼±ÕÀÇ ¼¼Æ÷º® ÇÕ¼ºÀ» ÀúÇØÇÑ´Ù.
- ¼¼Æ÷º® Çü¼ºÀÌ Â÷´ÜµÇ¸é¼ ¼¼Æ÷º®ÀÇ ÀÚ°¡ºÐÇØÈ¿¼Ò (autolysins, murein hydrolases µî)ÀÇ È°¼º¿¡ ÀÇÇÏ¿© °á±¹¿¡´Â ¼¼Æ÷°¡ ¿ëÇصȴÙ.
|
|
Clinical Uses |
- ±¹³» ½ÂÀÎ È¿´É : °¨¼ö¼º ÀÖ´Â ¼¼±Õ¿¡ ÀÇÇÑ ´ÙÀ½ °¨¿°Áõ :
- ±â°üÁöÈ®ÀåÁõ (°¨¿°½Ã), ¼¼±Õ¼º Æó·Å
- ÁßÀÌ¿°, À¯¾çµ¹±â¿°, ºÎºñ°¿°
- Æíµµ¿°, Àεο°
- ±Þ·¸¸¼º ½Å¿ì½Å¿°, ¹æ±¤¿°, Àü¸³¼±¿°
- »êºÎÀΰú °¨¿°Áõ
- ÇǺΠ¹× ¿¬Á¶Á÷ °¨¿°Áõ, °ñ °¨¿°Áõ
- ÀÓÁú ¹× ¸Åµ¶ : ´Ü, ȯÀÚ°¡ penicillins¿¡ °ú¹ÎÁõÀÎ °æ¿ì
- À¯È¿±ÕÁ¾ : Enterobacter, Enterococcus, Klebsiella, Pneumococcus, Escherichia coli, Haemophilus influenzae, Neisseria gonorrhoeae, Proteus mirabilis, Staphylococcus aureus, S. epidermidis, Streptococcus pyogenes, Treponema pallidum
|
|
Pharmacokinetics |
- Cephalexin :
- Èí¼ö : ¾î¸° ¼Ò¾Æ¿¡¼´Â Áö¿¬µÈ´Ù. ½Å»ý¾Æ¿¡¼ 50%±îÁö Èí¼ö°¡ °¨¼ÒÇÒ ¼ö ÀÖ´Ù.
- ºÐÆ÷ :
- ´ã³¶, °£, ½ÅÀå, »À, Ÿ¾×, ´ãÁó, ´Á¸·¾×, È°¾×À» Æ÷ÇÔÇÏ¿© ´ëºÎºÐÀÇ Ã¼³» Á¶Á÷°ú ü¾×¿¡ ³Î¸® ºÐÆ÷ÇÑ´Ù.
- ³úô¼ö¾×À¸·ÎÀÇ ºÐÆ÷´Â ¹Ì¹ÌÇÏ´Ù.
- ÅÂ¹Ý Åë°ú, À¯Áó ºÐÆ÷
- ´Ü¹é°áÇÕ : 6-15%
- ¹Ý°¨±â :
- ½Å»ý¾Æ : 5½Ã°£
- 3-12°³¿ùÀÇ ¼Ò¾Æ : 2.5 ½Ã°£
- ¼ºÀÎ : 0.5-1.2 ½Ã°£ (½ÅÀå¾Ö½Ã ¿¬Àå)
- Methylol cephalexin lysinate´Â cephalexinº¸´Ù ¹Ý°¨±â°¡ ´õ ±æ´Ù°í Á¦Á¶È¸»ç¿¡¼´Â º¸°íÇÏ¿´´Ù.
- Ç÷ÁßÃÖ°í³óµµ µµ´Þ½Ã°£ : °æ±¸ : 1½Ã°£ À̳»
- ¼Ò½Ç : 8½Ã°£ À̳»¿¡ 80-100%°¡ ¹Ìº¯Èü·Î ½Å¹è¼³
|
|
Usual Dosage |
- ±ÙÀ°ÁÖ»ç, Á¤¸ÆÁÖ»ç :
- À¯¾Æ ¹× ¼Ò¾Æ : 50-100 mg/kg/day, 1ÀÏ 3-4ȸ ºÐÇÒ Åõ¿©
- ¼ºÀÎ : °æÁõ : 1-2 g/day, 1ÀÏ 2ȸ ºÐÇÒ Åõ¿©
|
|
Adverse Reactions |
- °¡²û ÀϾ´Â ºÎÀÛ¿ë
- À§Àå°ü°è : ¿À½É, ±¸Åä, ¼³»ç, ¿¬º¯, º¹Åë, ½Ä¿åºÎÁø, À§ºÎºÒÄè°¨
- µå¹°°Ô ÀϾ´Â ºÎÀÛ¿ë
- °£ : Ȳ´Þ, GOT/GPT ¹× alkaline phosphatase »ó½Â
- ºñ´¢»ý½Ä°è : ±Þ¼º ½ÅºÎÀü
- À§Àå°ü°è : À§¸·¼º ´ëÀå¿°, ±¸³»¿°
- ÁßÃ߽Űæ°è : µÎÅë, Çѱâ, Àü½Å±ÇÅ°¨
- ÇǺΠ: Áßµ¶¼º Ç¥ÇDZ«»çÁõ
- Ç÷¾×°è : °ú¸³±¸°¨¼ÒÁõ, È£»ê±¸Áõ°¡Áõ, ¿ëÇ÷¼º ºóÇ÷, Ç÷¼ÒÆÇ°¨¼ÒÁõ, ¹éÇ÷±¸°¨¼ÒÁõ
- È£Èí±â°è : °£Áú¼º Æó·Å, PIE ÁõÈıº
- ±âŸ : ¼îÅ©, ĵð´ÙÁõ, vitamin K °áÇÌÁõ (ÀúÇÁ·ÎÆ®·ÒºóÇ÷Áõ, ÃâÇ÷ °æÇâ), vitamin Bs °áÇÌÁõ (¼³¿°, ±¸³»¿°, ½Ä¿åºÎÁø, ½Å°æ¿°)
- ºÎÀÛ¿ë ºóµµ ¹ÌÈ®ÀÎ
|
|
Overdosage / Toxicology |
- Cephalexin :
- Áßµ¶ Áõ»ó : ±Ù½Å°æ°è °ú¹Î¼º, ¹ßÀÛ(ƯÈ÷ ½ÅÀå¾Ö ȯÀÚ¿¡¼)
- Ä¡·á :
- ´ëºÎºÐ ÁöÁö¿ä¹ý°ú ´ëÁõ¿ä¹ýÀ¸·Î Ä¡·áµÉ ¼ö ÀÖ´Ù.
- ½ÉÇÑ Áßµ¶½Ã¿¡´Â Ç÷¾×Åõ¼®ÀÌ Ç÷ÁßÀÇ ¾à¹°À» ¼Ò½Ç½ÃÅ°´Âµ¥ µµ¿òÀÌ µÉ ¼öµµ ÀÖ´Ù.
|
|
Contraindications |
- º» ¾à¹°, cephalosporins¿¡ °ú¹Î¼º
|
|
Precautions |
- ´ÙÀ½ÀÇ °æ¿ì¿¡´Â ÁÖÀÇÇÏ¿© »ç¿ëÇÑ´Ù. :
- Penicillins¿¡ °ú¹Î¼º
- ÁßÁõÀÇ ½Å±â´ÉºÎÀü
- º»ÀÎ, °¡Á· Áß ±â°üÁöõ½Ä, ¹ßÁø, ´ã¸¶Áø µîÀÇ ¾Ë·¯Áö Áõ»óÀ» ÀÏÀ¸Å°±â ½¬¿î üÁúÀÌ Àִ ȯÀÚ
- °æ±¸ ¼·Ãë°¡ ºÒ·®ÇÑ È¯ÀÚ, ºñ°æ±¸ ¿µ¾ç ȯÀÚ
- °í·ÉÀÚ, Àü½Å»óÅ°¡ ³ª»Û ȯÀÚ
- ÁßÁõÀÇ ½ÅÀå¾Ö ȯÀÚ¿¡¼´Â ¿ë·® Á¶ÀýÀÌ ÇÊ¿äÇÏ´Ù.
- Àå±â°£ »ç¿ëÇÒ ¶§ Áߺ¹°¨¿°À» ÃÊ·¡ÇÒ ¼ö ÀÖ´Ù.
- µå¹°°Ô À§¸·¼º ´ëÀå¿°À» ÃÊ·¡ÇÒ ¼ö ÀÖ´Ù.
- ³»¼º±Õ ¹ßÇö µîÀ» ¹æÁöÇϱâ À§ÇÏ¿© ¿øÄ¢ÀûÀ¸·Î °¨¼ö¼ºÀ» È®ÀÎÇÑ ÈÄ Ä¡·á»ó ÇÊ¿äÇÑ ÃּұⰣ¸¸ Åõ¿©ÇÏ¿©¾ß ÇÑ´Ù.
- ¼îÅ© µîÀÇ ¹ÝÀÀÀ» ¿¹ÃøÇϱâ À§ÇÏ¿© ÃæºÐÈ÷ ¹®ÁøÇÏ°í Åõ¿© Àü¿¡ ÇǺιÝÀÀ½ÃÇèÀ» ½Ç½ÃÇÏ´Â °ÍÀÌ ¹Ù¶÷Á÷ÇÏ´Ù.
- ¼îÅ© ¹ß»ý¿¡ ´ëºñÇÏ¿© ±¸±Þóġ¸¦ ÁغñÇØ µÎ°í, Åõ¿© ÈÄ¿¡µµ ȯÀÚ¸¦ ¾ÈÁ¤ÇÑ »óÅ¿¡¼ ÃæºÐÈ÷ °üÂûÇØ¾ß ÇÑ´Ù.
|
|
Pregnancy Implication |
- Àӽźο¡¼´Â ¾ÈÀü¼ºÀÌ È®¸³µÇ¾î ÀÖÁö ¾Ê´Ù. À¯ÀͼºÀÌ À§Ç輺À» »óȸÇÏ´Â °æ¿ì¿¡ ÇÑÇÏ¿© »ç¿ëÇϵµ·Ï ÇÑ´Ù.
|
|
Stability |
- ¹èÇÕºÒ°¡ : °íºÐÀÚ·® ¹°ÁúÀÇ ¿ë¾×
|
|
Interactions |
- Cephalexin :
- È¿°ú Áõ°¡ : °í¿ë·®ÀÇ probenecid : CephalexinÀÇ Å¬¸®¾î·±½º°¡ °¨¼ÒÇÑ´Ù.
- µ¶¼º Áõ°¡ : Aminoglycosides : ½Åµ¶¼º À§Ç輺ÀÌ Áõ°¡ÇÑ´Ù.
¡Ø °Ë»ç»ó »óÈ£ÀÛ¿ë
- ÇãÀ§¾ç¼º¹ÝÀÀ : ´¢´ç °Ë»ç (Benedict ½Ã¾×, Fehling ½Ã¾×, ClinitestR)
- ¾ç¼º¹ÝÀÀ : Coombs ½ÃÇè (Á÷Á¢¹ý)
|
|
monitoring parameters |
- Àå±â°£ Åõ¿©½Ã : Á¤±âÀûÀ¸·Î ½Å±â´É°Ë»ç, °£±â´É°Ë»ç, Á¶Ç÷°è °Ë»ç
|
|
Nursing Implications |
- ¼îÅ© µîÀÇ ¹ÝÀÀÀ» ¿¹ÃøÇϱâ À§ÇÏ¿© ÃæºÐÈ÷ ¹®ÁøÇÏ°í Åõ¿© Àü¿¡ ÇǺιÝÀÀ½ÃÇèÀ» ½Ç½ÃÇÏ´Â °ÍÀÌ ¹Ù¶÷Á÷ÇÏ´Ù.
¡Ø Åõ¿©½Ã ÁÖÀÇ»çÇ×
- Ç÷Áß ÃÖ°í³óµµ¿Í ÃÖÀú³óµµÀÇ º¯È¸¦ ÃÖ¼ÒÈÇϱâ À§ÇØ ÀÏÁ¤ÇÑ ½Ã°£°£°ÝÀ¸·Î Åõ¿©Çϵµ·Ï ÇÑ´Ù.
|
|
Additional Information |
- Methylol cephalexin lysinate 1000 mgÀº cephalexin 658 mg¿¡ ÇØ´çÇÑ´Ù.
|
|
Reference |
- Á¦Á¶È¸»çÀÇ ³»¿ë¼³¸í¼
- Cephalexin :
- Lacy C, Armstrong LL, Ingrim N, Lance LL, eds. Drug information handbook, 4th edit. (1996), Lexi-Comp Inc.
- Drug information. In: CCIS (Clinical Computerized Information System), Vol. 93, Micromedex, Inc.
- Drug facts and comparisons, 1998 edition, 52nd edit. Facts and Comparisons
- Anderson PO, Knoben JE, eds. Handbook of clinical drug data, 8th edit. (1997), Appleton & Lange
|
|
|
|